Wave Life Sciences (WVE) Shares Outstanding (Weighted Average) (2014 - 2026)
Wave Life Sciences posted quarterly Shares Outstanding (Weighted Average) of $200.2 million for Q1 2026, up 23.13% year-on-year from $162.6 million in Q1 2025, and up 18.69% on a QoQ basis from $168.6 million in Q4 2025.
Wave Life Sciences (WVE) has 13 years of Shares Outstanding (Weighted Average) data on file, last reported at $200.2 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 23.13% year-over-year to $200.2 million; the trailing twelve-month figure through Mar 2026 stood at $200.2 million (up 23.13% YoY), and the FY2025 full-year result was $168.6 million, up 21.96% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $200.2 million, up from $168.6 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $200.2 million in Q1 2026 and bottomed at $7.1 million in Q2 2024.
- The 5-year median for Shares Outstanding (Weighted Average) is $105.5 million (2023), against an average of $107.3 million.
- The widest annual swing landed in 2024, when Shares Outstanding (Weighted Average) plunged 93.27%; it then jumped 2211.75% in 2025.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $78.9 million in 2022, then jumped by 34.55% to $106.1 million in 2023, then jumped by 30.33% to $138.3 million in 2024, then grew by 21.96% to $168.6 million in 2025, then grew by 18.69% to $200.2 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $200.2 million (Q1 2026), $168.6 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Wave Life Sciences | 1.32 Bn | 772.50 Mn | - | 200.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200.17 Mn |
| Dec 31, 2025 | 168.65 Mn |
| Sep 30, 2025 | 8.97 Mn |
| Jun 30, 2025 | 163.99 Mn |
| Mar 31, 2025 | 162.57 Mn |
| Dec 31, 2024 | 138.28 Mn |
| Sep 30, 2024 | 130.47 Mn |
| Jun 30, 2024 | 7.09 Mn |
| Mar 31, 2024 | 129.27 Mn |
| Dec 31, 2023 | 106.10 Mn |
| Sep 30, 2023 | 104.53 Mn |
| Jun 30, 2023 | 105.46 Mn |
| Mar 31, 2023 | 102.06 Mn |
| Dec 31, 2022 | 78.86 Mn |
| Sep 30, 2022 | 93.90 Mn |
| Jun 30, 2022 | 63.51 Mn |
| Mar 31, 2022 | 60.52 Mn |
| Dec 31, 2021 | 51.83 Mn |
| Sep 30, 2021 | 50.71 Mn |
| Jun 30, 2021 | 49.22 Mn |
| Mar 31, 2021 | 49.10 Mn |
| Dec 31, 2020 | 39.23 Mn |
| Sep 30, 2020 | 36.02 Mn |
| Jun 30, 2020 | 34.84 Mn |
| Mar 31, 2020 | 34.46 Mn |
| Dec 31, 2019 | 33.87 Mn |
| Sep 30, 2019 | 33.72 Mn |
| Jun 30, 2019 | 33.43 Mn |
| Mar 31, 2019 | 32.60 Mn |
| Dec 31, 2018 | 28.97 Mn |
| Sep 30, 2018 | 28.80 Mn |
| Jun 30, 2018 | 29.14 Mn |
| Mar 31, 2018 | 27.92 Mn |
| Dec 31, 2017 | 26.51 Mn |
| Sep 30, 2017 | 26.08 Mn |
| Jun 30, 2017 | 26.90 Mn |
| Mar 31, 2017 | 23.53 Mn |
| Dec 31, 2016 | 22.80 Mn |
| Sep 30, 2016 | 22.57 Mn |
| Jun 30, 2016 | 22.13 Mn |
| Mar 31, 2016 | 21.55 Mn |
| Dec 31, 2015 | 10.50 Mn |
| Sep 30, 2015 | 8.90 Mn |
| Jun 30, 2015 | 8.73 Mn |
| Mar 31, 2015 | 8.27 Mn |
| Dec 31, 2014 | 3.91 Mn |
| Sep 30, 2014 | 4.26 Mn |